Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

29 Mar 2022

Abstract excerpt

Frontline arsenic trioxide (ATO)-based treatment regimens achieve high rates of long-term relapse-free survival in treating acute promyelocytic leukemia (APL) and form the current standard of care. Refining prognostic estimates for newly diagnosed patients treated with ATO-containing regimens remains important in continuing to improve outcomes and identify patients who achieve suboptimal outcomes. We performed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Advanced biosensing and bioanalysis techniques
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35349669
DOI: 10.1182/bloodadvances.2021006682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaPMID 35349669Read ↗

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Semantic proximity Read ↗

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)Semantic proximity Read ↗

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.Semantic proximity Read ↗

Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.Semantic proximity Read ↗

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 studySemantic proximity Read ↗

Optimal treatment strategies for high-risk acute promyelocytic leukemiaSemantic proximity Read ↗

Prognostic impact of pretreatment cytogenetics in adult P hiladelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual diseaseSemantic proximity Read ↗

Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.Semantic proximity Read ↗

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Semantic proximity Read ↗

Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationSemantic proximity Read ↗

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.